Fig. 1: RPL22L1 is elevated in GBM patients and associated with poor prognosis of GBM. | Cell Death & Disease

Fig. 1: RPL22L1 is elevated in GBM patients and associated with poor prognosis of GBM.

From: RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma

Fig. 1

A RPL22L1 mRNA levels in GBM tissues were analyzed in GEO datasets through Oncomine platform (GSE4290, GSE30338, GSE7696, https://www.oncomine.org). B RPL22L1 mRNA was compared between normal brain tissues (n = 5) and GBM tissues (n = 167) in the TCGA dataset. Data were presented as the mean ± SD, ***P < 0.001, Student’s t test. C Kaplan-Meier survival analysis according to RPL22L1 mRNA levels in GBM patients (n = 882, Log-rank test, P = 0.012 HR = 1.2564, 95%CI, 1.0515–1.5014) from GEO datasets (GSE42669, GSE4412, GSE7696), CGGAarry, CGGAseq and TCGA combined. D IHC staining statistics of RPL22L1 protein in normal brain tissues (n = 6) and GBM tissues (n = 91) in TMAs. The staining score = staining intensity (0–3) × staining area ratio (0–100%). ***P < 0.001, Student’s t test. E Representative images of four levels of RPL22L1 IHC staining in GBM tissues (magnification×400, scale bar = 50 μm). F The expressions of RPL22L1 protein in clinical GBM tissues (T) and paired adjacent tissues (N) were detected by Western Blot (n = 6), GAPDH was the internal reference.

Back to article page